Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9651263 | 1.00 | FAAH (0.59) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL2269347 | 1.00 | FAAH (0.59) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| Alanine SCHEMBL4454120 | 0.92 | FAAH (0.53) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL9864028 | 0.92 | FAAH (0.53) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL5966860 | 0.87 | FAAH (0.70) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL5296255 | 0.87 | FAAH (0.70) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL5966857 | 0.87 | FAAH (0.70) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL9377518 | 0.85 | FAAH (0.78) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL5936930 | 0.85 | FAAH (0.78) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 | |
| SCHEMBL101698 | 0.85 | FAAH (0.78) | FAAHALDH1A1MAPTSMN1; SMN2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101050217-A | Method for synthesizing Vardenafil hydrochloric acid | UNIV BEIJING CHEMICAL (CN) | 2007-10-10 | — | — | CN | claimed |
| EP-3366273-B1 | MOISTURIZER AND COSMETIC CONTAINING SAME | AJINOMOTO KK (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2025-01-02 | — | — | US | disclosed |
| EP-4433093-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-09-25 | — | — | EP | disclosed |
| EP-4299057-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023084118-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | ADOCIA (FR) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180060-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | Adocia (FR) | 2023-05-17 | — | — | EP | disclosed |
| US-10406086-B2 | Moisturizer and cosmetic including the same | AJINOMOTO CO., INC. (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-3366273-A1 | MOISTURIZER AND COSMETIC CONTAINING SAME | Ajinomoto Co., Inc. (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-20180185256-A1 | MOISTURIZER AND COSMETIC INCLUDING THE SAME | AJINOMOTO CO., INC. (JP) | 2018-07-05 | — | — | US | disclosed |
| EP-1049695-B1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2002-02-13 | — | — | EP | disclosed |
| EP-1174431-A2 | 2-Phenyl-substituited Imidazotriazinones as Phoshodiesterase Inhibitors | Bayer Aktiengesellschaft (DE) | 2002-01-23 | — | — | EP | disclosed |
| WO-2001064677-A1 | NOVEL IMIDAZOTRIAZINONES AND THE USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-07 | — | — | WO | disclosed |
| EP-1082127-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1049695-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AG (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999056765-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999024433-A1 | 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-05-20 | — | — | WO | disclosed |
| US-4308384-A | Production of triazinones | GLAXO GROUP LIMITED (GB) | 1981-12-29 | — | — | US | disclosed |
| US-4278673-A | Pharmacologically active compounds | ALLEN & HANBURYS LIMITED (GB) | 1981-07-14 | — | — | US | disclosed |
| EP-0009384-A1 | Processes for the preparation of triazinones and condensed triazinones, and compounds so obtained | GLAXO GROUP LIMITED (GB) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000948-A1 | SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID | NPPA, BCAT1, ANPEP | FAAH 858/4885ALDH1A1 4701/4885MAPT 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.